Abstract
Prostate cancer is an increasingly prevalent health problem among males, and the need for improved methods of treatment is great. In the 1940s estrogens were shown to be of benefit in prostate cancer, and their use continued for some 30 years, until the advent of LHRH agonists and similar drugs. At the time the mechanism of action of estrogens was thought to involve merely reduction in androgen levels, but new evidence, including expression of estrogen receptors by prostate epithelium and prostate cancer results showing a direct cytotoxic effect on prostate cancer, and preclinical data on inhibition of prostate cancer in intact female mice, suggests that estrogen exerts other effects on prostate cancer cells. Given that estrogens also decrease bone lysis caused by androgen suppression and may ameliorate cognitive side effects associated with low testosterone, estrogens show promise in treatment of androgen-independent prostate cancer. This review summarizes published reports of the effects on estrogens on prostate cancer in preclinical and clinical settings.
Keywords: Prostate cancer, estrogen, estradiol
Current Cancer Therapy Reviews
Title: Estrogen in Prostate Cancer - Friend or Foe?
Volume: 2 Issue: 4
Author(s): Eva Corey
Affiliation:
Keywords: Prostate cancer, estrogen, estradiol
Abstract: Prostate cancer is an increasingly prevalent health problem among males, and the need for improved methods of treatment is great. In the 1940s estrogens were shown to be of benefit in prostate cancer, and their use continued for some 30 years, until the advent of LHRH agonists and similar drugs. At the time the mechanism of action of estrogens was thought to involve merely reduction in androgen levels, but new evidence, including expression of estrogen receptors by prostate epithelium and prostate cancer results showing a direct cytotoxic effect on prostate cancer, and preclinical data on inhibition of prostate cancer in intact female mice, suggests that estrogen exerts other effects on prostate cancer cells. Given that estrogens also decrease bone lysis caused by androgen suppression and may ameliorate cognitive side effects associated with low testosterone, estrogens show promise in treatment of androgen-independent prostate cancer. This review summarizes published reports of the effects on estrogens on prostate cancer in preclinical and clinical settings.
Export Options
About this article
Cite this article as:
Corey Eva, Estrogen in Prostate Cancer - Friend or Foe?, Current Cancer Therapy Reviews 2006; 2 (4) . https://dx.doi.org/10.2174/157339406778699231
DOI https://dx.doi.org/10.2174/157339406778699231 |
Print ISSN 1573-3947 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-6301 |
Call for Papers in Thematic Issues
Current progress in Protein Degradation and Cancer Therapy
argeted Protein Degradation is gaining momentum in cancer therapy, it facilitate targeting undruggable proteins, it overcome cancer resistance and avoid undesirable side effects. Thus small molecules degraders have emerged as novel therapeutic strategy. Targeted protein degradation (TPD), the process of eliminating a protein of interest hold a great promise for ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Structural Magnetic Resonance Imaging Findings in Posttraumatic Stress Disorder and Their Response to Treatment: A Systematic Review
Current Psychiatry Reviews Reversal of Resistance to Oxazaphosphorines
Current Cancer Drug Targets New Insights into the Binding Mechanism of Co-regulator BUD31 to AR AF2 Site: Structural Determination and Analysis of the Mutation Effect
Current Computer-Aided Drug Design International Conference on Personalized Medicine: “Genes and Medicine” 19-20 September 2009, Hong Kong Science Park, Hong Kong SAR
Current Pharmacogenomics and Personalized Medicine Strategies to Overcome Drug Resistance of Receptor Tyrosine Kinaseaddicted Cancer Cells
Current Medicinal Chemistry Personalized & Precision Medicine in Cancer: A Theranostic Approach
Current Radiopharmaceuticals Diagnostic Value of MiR-125b as a Potential Biomarker for Stage I Lung Adenocarcinoma
Current Molecular Medicine Harnessing Impaired Energy Metabolism in Cancer Cell: Small Molecule- Mediated Ways to Regulate Tumorigenesis
Anti-Cancer Agents in Medicinal Chemistry Carotenoids as Modulators of Intracellular Signaling Pathways
Current Signal Transduction Therapy Dietary Antioxidants and Oxidative Stress from a Human and Plant Perspective: A Review
Current Nutrition & Food Science Multi-target Activities of Selected Alkaloids and Terpenoids
Mini-Reviews in Organic Chemistry The Therapeutic Potential of RNA Interference: Novel Approaches for Cancer Treatment
Current Pharmaceutical Biotechnology Thermal Assisted In Vivo Gene Electrotransfer
Current Gene Therapy Combination Therapy for the Treatment of Pancreatic Cancer
Anti-Cancer Agents in Medicinal Chemistry Charge Deficient Analogues of the Natural Polyamines
Current Pharmaceutical Design Central Nervous System Neoplasms in Hong Kong: An Inscription of Local Studies
Current Cancer Therapy Reviews Production of Orally Applicable New Drug or Drug Combinations from Natural Origin Capsaicinoids for Human Medical Therapy
Current Pharmaceutical Design Exploring the Synthesis and Anticancer Potential of L-Tyrosine-Platinum(II) Hybrid Molecules
Medicinal Chemistry A Review on Structures and Functions of Bcl-2 Family Proteins from Homo sapiens
Protein & Peptide Letters 1α ,25(OH)2-Vitamin D3 and 17β-Estradiol: Two Steroid Partners Acting in Skeletal Muscle
Immunology, Endocrine & Metabolic Agents in Medicinal Chemistry (Discontinued)